The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Nat Metab. 2020 Dec;2(12):1401-1412. doi: 10.1038/s42255-020-00316-0. Epub 2020 Nov 30. Nat Metab. 2020. PMID: 33257855 Free PMC article.